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Abstract 
Infective endocarditis (IE) is uncommon in children, affecting predominantly 
subjects with congenital heart disease (CHD) and patients with indwelling central 
lines. The principles of antibiotic treatment in pediatric population are similar to 
those in adults. Prolonged intravenous administration of bactericidal rather than 
bacteriostatic agents is preferred. Outpatient intravenous therapy after initial 
treatment in the hospital may be considered only in selected patients. Partial oral 
treatment has been described in cases of left-sided, uncomplicated IE caused by 
common pathogens in adult patients. There are no guidelines or trials in pediatric 
population regarding switching therapy from intravenous to oral route. We 
present two cases of IE in children caused by uncommon pathogenic bacteria 
(Abiotrophia defectiva and Haemophilus parainfluenzae) successfully treated 
with oral third-generation cephalosporin - cefpodoxime proxetil after initial 
intravenous therapy. This paper provides observations on different therapeutic 
approach for IE in children as well as another potential use of cefpodoxime 
proxetil. 
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Introduction 
 
In the last two decades, congenital heart disease (CHD) has been the predominant 
underlying condition for IE in children older than two years of age residing in 
developed countries. Children with central venous catheters, especially newborns, are at 
higher risk for developing IE as well [1]. The incidence of IE in this time period has 
remained unchanged, but a slight shift towards community acquired IE has been noticed 
[2]. Interestingly, in up to 10% of all cases of IE diagnosed in children, there are no 
structural cardiac disease or identifiable risk factors present [1]. Among children with 
underlying CHD, Streptococcus and Staphylococcus spp are equally and the most 
frequently isolated pathogens, while in patients with structurally normal heart, 
Staphylococcus aureus causes approximately 50% of cases [3]. The isolation of the 
causative microorganism accompanied by susceptibility testing is crucial for appropriate 
antimicrobial treatment. Although dosage and, in some cases, the choice of antibiotics 
for children differs from those in adults, general therapeutic principles and duration of 
antibiotic treatment remain similar for all age groups. The recommendations for the 
duration of antimicrobial treatment are mainly based on the characteristics of the 
infecting organism and usually last for 4-8 weeks. General consensus is that the 
antibiotic should be given intravenously and the outpatient intravenous treatment can be 
considered only in selected patients after initial treatment in the hospital. Oral 
antibiotics can be the convenient alternative in adults with limited options for effective 
intravenous therapy (resistant bacteria or patients with multiple allergies) or when 
prolonged intravenous access is not possible or is undesirable (intravenous drug users). 
However, the role of oral therapy in treating IE is not well established and reports about 
switching therapy from intravenous (IV) to oral during treatment are still lacking, 
especially in pediatric population.  
This paper gives observations on two children with IE caused by unusual 
bacteria treated with oral third-generation cephalosporin after initial IV therapy. 
Additionally, these cases give further information about the efficacy and safety of 
cefpodoxime proxetil as the treatment option for pediatric IE.   
  
Case presentation 
Case 1   
A previously healthy 5.5-year-old girl was admitted to the Pediatric Department at the 
University Hospital for Infectious Diseases (UHID) in Zagreb, Croatia, following a 46-
day history of low-grade fever and fatigue. Her past medical history was unremarkable. 
Empirical treatment with oral cefixime was started early in the course of illness. During 
treatment her symptoms resolved, but soon after discontinuation of therapy the fever 
relapsed. Diagnostic tests obtained in a local hospital where she was first examined, 
revealed positive IgM and negative IgG antibody to cytomegalovirus (CMV). 
Laboratory findings showed slightly elevated liver enzymes and she was discharged 
with the diagnosis of a recent CMV infection. As her symptoms persisted for the next 3 
weeks, she presented to our pediatric emergency department. On physical examination, 
she was well-appearing with normal vital signs and low-grade fever (37.5⁰C). 
Cardiovascular examination demonstrated systolic murmur grade II/VI along the left 
sternal border. The liver and spleen were both palpable for 3 cm below the costal 
margins. The initial laboratory investigations revealed slightly elevated C-reactive 
protein (14.2 mg/L), mild anemia (hemoglobin 9.9 g/dL; hematocrit 30.2%) with 
normal erythrocyte sedimentation rate (10 mm/hour), WBC count (5200 cells⁄microL, 
ANC 3614 /microL) and platelet count (240 000 ⁄microL). Liver and renal function tests 
were within normal ranges. Repeated serological test for CMV gave completely 
negative results. Chest radiography revealed cardiac enlargement and abdominal 
ultrasound confirmed hepatosplenomegaly. Culture of blood drawn on the first visit to 
UHID yielded Abiotrophia defectiva and intravenous ampicillin (300 mg/kg/day divided 
q6h) and gentamicin (7 mg/kg/day divided q8h) were initiated. The patient became 
afebrile following the 1st day of treatment and her fatigue resolved within a week. 
Although vegetations or abscesses were not detected, transthoracic echocardiogram 
(TTE) showed previously undiagnosed small patent ductus arteriosus. Based on this 
echocardiographic finding, the isolation of A. defectiva from 5 sets of blood cultures and 
clinical presentation, subacute endocarditis was diagnosed. On the 5th day of treatment, 
A. defectiva isolate was found to be sensitive to cephalosporins and ampicillin was 
changed to ceftriaxone (100 mg/kg/day divided q12h). After 18 days of combined IV 
therapy, the treatment was switched to oral cefpodoxime proxetil (10 mg/kg/day divided 
q12 h) for 6 weeks in total. All blood cultures drawn after the initiation of treatment 
with ceftriaxone remained sterile. The treatment with cefpodoxime proxetil was well 
tolerated and there were no adverse events related to drug therapy. Transcatheter closure 
of PDA was done 3 months after treatment completion. The patient recovered 
completely and at the cardiology follow-up visit after another 2 months no sequelae or 
relapses of the disease were found. 
 
Case 2 
A 6.5–year-old male child was admitted to the UHID on the 26th day of febrile illness. 
The patient had a history of congenital heart disese and underwent surgical conduit 
replacement after total correction of the truncus arteriosus communis (type I according 
to Collett and Edwards) by Rastelli procedure 5 years prior to current illness. On the 1st 
day of acute onset of a high-grade fever up to 40 ⁰C, a 14-day course of oral 
amoxicillin/clavulanate therapy was started. Other symptoms included headache, sore 
throat, abdominal pain and vomiting. After three days of therapy the fever resolved, but 
on the 12th day of disease, fever increased up to 39 ⁰C accompanied with night sweats 
and chills. The treatment was switched to oral cefuroxime axetil but without any clinical 
effect. On the 21st day of illness, the patient was hospitalised in a local hospital in 
Coastal Croatia with presumptive diagnosis of infective endocarditis and empiric 
intravenous therapy with vancomycin and meropenem was initiated. The patient became 
afebrile the following day but diagnostic tests didn´t confirm the diagnosis of 
endocarditis therefore he was transferred to the UHID. On admission, the patient was 
well-appearing, afebrile and with normal vital signs. Physical examination revealed a 
pansystolic murmur best heard over the 3rd and the 4th left intercostal spaces. The 
patient's WBC count was 7000 /microL and his C-reactive protein level was 20.6 mg/L. 
In the next 3 days the antibiotic therapy was discontinued and several blood cultures 
were obtained which were all negative. On the 4th day of hospitalization, the patient 
became febrile again, up to 39.1 ⁰C.The laboratory findings showed elevated C-reactive 
protein (234.3 mg/L) and erythrocyte sedimentation rate (85 mm/hour). Furthermore, 
mild anemia (RBC 3.78 x106/microL; hemoglobin 9.4 g/dL; hematocrit 28.6%) and 
thrombocytopenia (127 000 /microL) were registered. After blood cultures were 
collected, the treatment with vancomycin (45 mg/kg/day divided q8h) and ceftriaxone 
(80 mg/kg/day in one daily dose) was initiated. The patient`s clinical condition 
improved rapidly and he became afebrile within 48 hours. Despite the fact that TTE as 
well as heart MR imaging didn`t reveal vegetations, infective endocarditis could not 
have been eliminated due to dysplastic aortic valve and degenerated conduit. PCR 
analysis of blood, using primers targeting the 16S rDNA sequence, was negative as well 
as the results of serologic examinations for Q fever and Brucella. However, one blood 
culture taken during febrile episode came positive for Haemophilus parainfluenzae. 
Since the organism was sensitive to third-generation cephalosporins, 9 days after the 
initiation vancomycin was discontinued and ceftriaxone monotherapy was administered 
for the next 6 days. Intravenous treatment was followed by oral cefpodoxime proxetil 
(10 mg/kg/day divided q12 h) for 6 weeks in total. Blood cultures drawn during and 
after IV therapy remained negative and the patient was discharged with full recovery. In 
the following two years after hospital discharge, the patient was in good condition, 
afebrile, without complaints and relapses of IE.  
 
Discussion 
Long-term parenteral treatment of IE represents a significant practical problem (risk of 
catheter-related infections, prolonged hospital stay) resulting with discomfort and 
anxiety in pediatric patients. Intravenous antibiotics are considered principal in the 
treatment of IE because they achieve rapid therapeutic concentrations in blood and 
perfused tissues and they are generally regarded as more potent and reliable than their 
oral equivalents. Although IV treatment remains the first choice for IE, few studies have 
showed that in uncomplicated cases of IE oral treatment could be effective and safe.  
Oral combination of ciprofloxacin and rimfapicin has showed efficacy in the 
right-sided S. aureus IE in adults in one randomized trial and one observational study 
[4,5]. This therapeutic strategy was associated with a favorable clinical outcome even in 
complicated left-sided endocarditis, but generally in a limited number of cases [6,7]. In 
a recently published retrospective study conducted in France from 2002-2012, 
researchers evaluated the outcomes in 426 patients (of whom 3 children) treated for IE 
with oral antibiotics after IV induction therapy [8]. The most common oral regimens 
were amoxicillin monotherapy or a combination of amoxicillin with clindamycin, a 
fluoroquinolone or rifampicin. The results showed that switching to peroral therapy was 
not associated with attributable risk for relapse or reinfection. However, patients in the 
oral group received on average 3 weeks of IV treatment and they were less severely ill. 
Furthermore, another trial performed at cardiac centers in Denmark from 2011 to 2017 
demonstrated similar results [9]. The study included 400 adults in stable condition with 
left-sided IE caused by streptococci, Enterococcus faecalis, Staphylococcuss aureus or 
coagulase-negative staphylococci. In all patients the antibiotic treatment was 
administered intravenously for at least 10 days. After a median of 17 days of IV 
therapy, 50% of all patients were treated orally for the next 19 days (range from 14 to 
25 days). Results showed that changing to oral antibiotic treatment was noninferior to 
continuous intravenous antibiotic therapy.  
To the best of our knowledge, no study has ever been published on IV/oral 
therapy switch for endocarditis in pediatric population, except the report of 14 episodes 
of subacute bacterial endocarditis in children treated in the 1960-1975 period [10]. All 
children reported were successfully treated, without relapses. No significant 
complications during treatment were recorded either. In 42% of cases the treatment was 
entirely oral and in other cases antibiotics were given parenterally just for the first 2 or 3 
days. Contrary to our cases, there were no unusual bacteria isolated from blood and in 
all cases the causative pathogens were streptococci, staphylococci and enterococci. The 
most frequently used antibiotic was ampicillin, while in some patients different 
penicillin derivatives (cloxacillin, flucloxacillin, penicillin V) and erythromycin were 
given. Other studies in which oral ampicillin and amoxicillin were used for treating 
mainly streptococcal IE, reported high response rates [11,12].  
Opposite to previously mentioned studies where cases of orally treated IE were 
caused by usual bacteria (Streptococcus viridans, Enterococcus faecalis, 
Staphylococcuss aureus or coagulase-negative staphylococci), in our patients 
uncommon microorganisms, Abiotrophia defectiva and Haemophilus parainflunezae, 
were isolated. Because of low bacterial virulence of these pathogens, we estimated that 
partial oral antibiotic treatment in reported cases was even more reasonable. 
Abiotrophia defectiva, formerly known as nutritionally variant streptococci (NVS) is a 
fastidious bacteria responsible for higher rates of complications than IE caused by other 
streptococci. Because of limited clinical data and reported high rates of resistance to 
penicillin, the American Heart Association (AHA) guidelines suggest treating NVS IE 
as enterococcal IE [1]. On the other hand, the European Society of Cardiology (ESC) 
guidelines differ slightly, as they recommend 6 weeks of benzylpenicillin, ceftriaxone 
or vancomycin, combined with an aminoglycoside for at least the first 2 weeks [13]. 
Additionally, the recommendations for the treatment of Haemophilus parainflunezae IE 
are similar to NVS IE and a 4-week course of ceftriaxone or another parenteral third-
generation cephalosporin alone are recommended.  
According to these guidelines, our patients were treated for the first 2 weeks 
with ceftriaxone combined with gentamicin or vancomycin. After a satisfactory clinical 
and laboratory response, the treatment was changed to oral cefpodoxime proxetil for 
another 4 weeks. This treatment option resulted in a complete recovery in both patients, 
without relapses of IE.  
Cefpodoxime proxetil is an oral, third-generation cephalosporin, widely used for 
the treatment of upper (pharyngitis/tonsillitis, otitis media) and lower (pneumonia, 
bronchitis) respiratory tract infections (usually administered 8 to 10 mg/kg/day in 2 
divided doses). It is a prodrug that is rapidly de-esterified in its active metabolite 
cefpodoxime during absorption. Clinical studies have demonstrated extensive 
distribution of cefpodoxime trough tonsils, bronchial mucosa, lung parenchyma, pleural 
and interstitial inflammatory fluid [14]. Due to significant distribution of the drug in 
urine, periodontal (gingival tissue, alveolar bone) structures and skin, cefpodoxime 
proxetil can be an adequate therapeutic option for urinary tract, skin and soft tissue 
infections as well [14]. One clinical study conducted on piglets showed low (about 5%) 
penetration of cefpodoxime into cerebrospinal fluid (CSF), but the concentration of the 
drug in CSF exceeded MIC90 values for the majority of bacteria that are usually 
susceptible to this drug [15]. There are no reports regarding cefpodoxime distribution in 
endocardial vegetations nor possible use of this antibiotic in the setting of IE. Although 
oral bioavailability of the drug is about 50%, cefpodoxime shows low plasma protein 
binding (ranging from 18-23%) and the plasma concentration of the antibiotic remains 
above 0.5 mg/L for at least 8 hours after oral administration [14,16]. In children, peak 
plasma concentrations (range from 3.7 to 5.5 mg/L) are achieved approximately 2 hours 
after a single oral dose of cefpodoxime proxetil (6 mg/kg) [14]. In comparison, typical 
doses of oral amoxicillin (1g, q8h), which has excellent bioavailability (>90%) and low 
binding to serum proteins (17%), produce peak and 6-hour serum concentrations of 16 
mg/L and 1.1 mg/L, respectively [7]. Because of favourable pharmacokinetic profiles in 
conjunction with the previously reported clinical efficacy, oral amoxicillin and 
penicillin V are considered a plausible alternative for the treatment of IE caused by 
susceptible bacteria, mainly streptococci.  On the other hand, cefpodoxime has a broad 
bactericidal activity against a wide range of gram-positive and gram-negative 
pathogens, including Streptococcus pneumoniae, other streptococci (but not 
enterococci), Haemophilus spp. (including β-lactamase-producing strains) and 
Moraxella catarrhalis. Furthermore, pharmacodynamic/pharmacokinetic analyses 
demonstrated that, compared to other cephalosporins (cefuroxime axetil, cefixime, 
ceftibuten), only cefpodoxime proxetil exceeds 90% of time above MIC90 values for 
susceptible pathogens (Streptococcus pneumoniae, Moraxella catarrhalis and 
Haemophilus spp.) [17]. Although streptococci continue to be the leading pathogens of 
IE, recent changes of attributable risk factors and causative, previously uncommon, 
pathogens for pediatric IE, have made cefpodoxime proxetil a reasonable alternative for 
oral treatment of IE.  
In conclusion, our clinical experience provides evidence for successful therapy 
of uncomplicated IE with cefpodoxime proxetil in pediatric population and emphasize 
the need for further investigation of this therapeutic approach. 
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